On this page
MCADD (atypical)
This rare autosomal recessive condition affects how the body processes medium-chain fatty acids during periods of fasting or illness. Without adequate glucose stores, individuals cannot efficiently convert these fats into usable energy, which can lead to serious metabolic complications if unrecognised.
Available at Jeen Health
Clinical tests that include this
Overview
Atypical MCADD represents a variant form of medium-chain acyl-CoA dehydrogenase deficiency, distinguished from classical MCADD by the specific pathogenic changes in ACADM. This inherited metabolic condition disrupts the breakdown of medium-chain fatty acids, which serve as important fuel sources when the body's glucose reserves become depleted during prolonged fasting, illness, or increased energy demands.
The atypical designation typically refers to cases where genetic changes in ACADM produce residual enzyme activity or result in milder or less predictable clinical presentations compared to the more common classical form. Research suggests that the clinical course can vary considerably between individuals, even within the same family, making recognition and appropriate management important. Early identification and dietary management strategies aim to reduce the risk of serious metabolic episodes.
Symptoms & clinical features
Clinical features of atypical MCADD often emerge during metabolic stress, particularly when an individual experiences prolonged fasting, viral illness, or gastrointestinal upset that prevents normal eating. During such episodes, affected individuals may develop hypoglycaemia with associated symptoms including lethargy, drowsiness, irritability, and reduced responsiveness. Some people experience vomiting, which can further exacerbate the metabolic crisis by preventing glucose intake.
In more severe decompensations, individuals may develop encephalopathy characterised by confusion, seizures, or altered consciousness. Between metabolic crises, many people with atypical MCADD remain entirely well and exhibit normal growth and development. The atypical form may present later in childhood or even adulthood compared to classical MCADD, and some affected individuals may experience milder symptoms or fewer episodes throughout their lifetime. However, the unpredictable nature of the condition means that vigilance during periods of illness or fasting remains important regardless of previous clinical course.
Video: Genetics 101
Affected organs
The metabolic disruption in atypical MCADD primarily affects organs with high energy demands, particularly the liver and brain. The liver plays a central role in processing fatty acids and maintaining blood glucose levels through gluconeogenesis, and impaired fat oxidation can lead to hepatic dysfunction during metabolic stress, sometimes manifesting as hepatomegaly or elevated liver enzymes.
The brain is especially vulnerable to hypoglycaemia and the accumulation of toxic metabolites that can occur during metabolic crises. Severe or prolonged episodes may potentially result in neurological complications, though appropriate emergency management typically prevents such outcomes. The heart muscle, which also relies on fatty acid oxidation for energy, may occasionally be affected, though cardiac involvement appears less prominent in atypical compared to some other fatty acid oxidation disorders.
Risks & severity
The severity of atypical MCADD varies considerably between individuals, influenced by the specific genetic changes present, residual enzyme activity, and environmental triggers. Some people experience only mild symptoms or remain asymptomatic throughout life if metabolic stress is avoided, whilst others may develop serious metabolic decompensation requiring urgent medical intervention. The most significant risk period occurs during intercurrent illness, particularly gastrointestinal infections that prevent normal feeding.
Without recognition and appropriate management, severe metabolic crises can lead to neurological injury, coma, or life-threatening complications. Adherence to emergency management protocols during illness, combined with avoidance of prolonged fasting, is important for reducing these risks. The unpredictable nature of atypical presentations means that individuals may remain well for extended periods before experiencing their first metabolic crisis, sometimes not until adulthood. Long-term outcomes are generally favourable when the condition is recognised and appropriate preventive measures are maintained throughout life.
Genetic causes
Atypical MCADD results from pathogenic variants in ACADM. This gene encodes medium-chain acyl-CoA dehydrogenase, a mitochondrial enzyme essential for breaking down medium-chain fatty acids, which typically contain 6 to 12 carbon atoms. The enzyme facilitates conversion of fats into usable energy, particularly when food intake is limited.
Pathogenic changes in ACADM impair the body's ability to process medium-chain fatty acids. In atypical MCADD, genetic alterations may produce enzyme variants with reduced but not completely absent activity, or affect protein stability in ways that differ from the more common classical form. These molecular alterations reduce the enzyme's efficiency in processing medium-chain fatty acids, leading to their accumulation and reduced energy production during fasting states. The specific nature of the genetic change influences the degree of residual enzyme function, which in turn affects clinical severity and presentation patterns. When fat breakdown is impaired, the body cannot adequately compensate for depleted glucose stores, potentially resulting in hypoglycaemia and the accumulation of incompletely processed fatty acid intermediates.
- ACADM acyl-CoA dehydrogenase medium chainThe ACADM gene encodes the medium-chain acyl-CoA dehydrogenase (MCAD) enzyme, which is vital for breaking down certain fats into energy within the body's cells.
Inheritance pattern
Atypical MCADD follows an autosomal recessive inheritance pattern, meaning that an individual must inherit two altered copies of ACADM - one from each parent - to develop the condition. People with only one pathogenic variant are carriers and typically remain unaffected throughout their lives, as the single functional copy of the gene provides sufficient enzyme activity for normal fat metabolism.
When both parents are carriers, each pregnancy has a 25% chance of resulting in an affected child, a 50% chance of producing a carrier child, and a 25% chance of a child who inherits two typical copies of the gene. Carrier testing is available for family members, and reproductive options including prenatal testing and preimplantation genetic testing can be discussed with clinical genetics services for families with a known ACADM pathogenic variant. The NHS Genomic Medicine Service provides access to genetic counselling to help families understand these inheritance patterns and make informed decisions about testing.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
Diagnosis of atypical MCADD usually relies on newborn bloodspot screening, which has been part of the NHS Newborn Blood Spot Screening Programme in the UK. The screening test identifies biochemical patterns that suggest impaired medium-chain fatty acid oxidation. Confirmatory testing includes molecular genetic analysis of ACADM to identify the specific pathogenic variants present, alongside additional biochemical studies measuring enzyme activity or metabolite profiles.
In individuals not identified through newborn screening, diagnosis may follow investigation of a metabolic crisis or unexplained hypoglycaemia during illness. The condition is categorised under NHS R-code R97 (disorders of mitochondrial fatty acid beta-oxidation) within the Genomic Medicine Service framework. Referral to a metabolic specialist through local paediatric or adult metabolic services enables comprehensive diagnostic evaluation and confirmation.
Management & lifestyle
Management of atypical MCADD focuses on preventing metabolic decompensation through avoidance of prolonged fasting and prompt intervention during illness. Individuals are typically advised to maintain regular meals and snacks, with specific guidance on maximum safe fasting intervals that vary by age. During episodes of illness, particularly those involving vomiting or reduced oral intake, an emergency regimen involving frequent glucose-containing drinks or snacks helps maintain blood glucose levels and prevents the metabolic switch to fat oxidation.
If oral intake cannot be maintained, urgent medical assessment is required, as intravenous glucose may be necessary to prevent serious hypoglycaemia. Many families receive written emergency management protocols to share with healthcare providers during acute presentations. Routine monitoring through specialist metabolic clinics enables adjustment of management strategies as children grow and energy requirements change. The approach for atypical cases may be individualised based on residual enzyme activity and previous clinical course. Genetic counselling is available through NHS clinical genetics services to discuss inheritance, family planning, and implications for relatives. Dietary modifications and emergency protocols remain the mainstay of management.
UK care pathway
Within the NHS Genomic Medicine Service, atypical MCADD falls under the inherited metabolic disorders category, typically managed through specialist metabolic medicine centres. Following newborn screening identification or clinical diagnosis, individuals are referred to a consultant with expertise in metabolic conditions who coordinates long-term care and monitoring. The relevant PanelApp virtual gene panel includes ACADM within R97 (disorders of mitochondrial fatty acid beta-oxidation), guiding genomic testing approaches.
Genetic counselling services are accessible through regional clinical genetics departments, providing support for affected individuals and their families regarding inheritance patterns, reproductive options, and cascade testing for at-risk relatives. Multidisciplinary care typically involves metabolic dietitians who provide detailed dietary guidance, specialist metabolic nurses who support emergency management planning, and liaison with local healthcare providers to ensure coordinated care during acute illness. Transition from paediatric to adult metabolic services is carefully planned to maintain continuity of care and ensure ongoing access to specialist expertise throughout life.
Frequently asked questions
Can my child with atypical MCADD participate in normal activities like sports?
Most children with atypical MCADD can participate fully in sports and physical activities with appropriate precautions. The key considerations are ensuring regular meals and snacks around activity times to maintain energy supply, and avoiding prolonged exertion without adequate food intake. Your metabolic team can provide specific guidance tailored to your child's activity level and residual enzyme function.
What should I do if my child vomits and cannot keep food down?
If vomiting prevents normal eating, offer frequent small sips of glucose-containing drinks such as diluted fruit juice or glucose solution every 15 to 30 minutes. If your child cannot tolerate oral fluids for more than a few hours, or becomes drowsy or unresponsive, seek urgent medical attention as intravenous glucose may be needed. Always share your emergency management protocol with treating healthcare providers.
Will atypical MCADD affect my child's learning or development?
With appropriate management to prevent metabolic crises, most children with atypical MCADD develop and learn normally. The condition itself does not directly cause learning difficulties when well managed. However, severe untreated metabolic episodes could potentially cause neurological complications, which is why prevention through dietary management and prompt illness intervention is so important.
Do siblings of someone with atypical MCADD need testing?
Siblings have a 25% chance of also having the condition and a 50% chance of being carriers. Testing can be arranged through your metabolic team or clinical genetics service, particularly for siblings born before newborn screening was introduced or in families where the diagnosis was made after the newborn period. Carrier testing may also be relevant for siblings planning their own families.
How often does my child need to eat to stay safe?
Safe fasting intervals vary by age and individual circumstances. Young infants typically need feeding every few hours, whilst older children may manage longer periods between meals. Your metabolic team will provide specific guidance tailored to your child's age, residual enzyme activity, and clinical history to ensure safe fasting limits are maintained.